144 related articles for article (PubMed ID: 32963176)
21. β-Arrestin1 and β-Arrestin2 Are Required to Support the Activity of the CXCL12/HMGB1 Heterocomplex on CXCR4.
D'Agostino G; Artinger M; Locati M; Perez L; Legler DF; Bianchi ME; Rüegg C; Thelen M; Marchese A; Rocchi MBL; Cecchinato V; Uguccioni M
Front Immunol; 2020; 11():550824. PubMed ID: 33072091
[TBL] [Abstract][Full Text] [Related]
22. β-Arrestin1 and 2 differentially regulate PACAP-induced PAC1 receptor signaling and trafficking.
Shintani Y; Hayata-Takano A; Moriguchi K; Nakazawa T; Ago Y; Kasai A; Seiriki K; Shintani N; Hashimoto H
PLoS One; 2018; 13(5):e0196946. PubMed ID: 29734363
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of heat shock protein 90 decreases ACTH production and cell proliferation in AtT-20 cells.
Sugiyama A; Kageyama K; Murasawa S; Ishigame N; Niioka K; Daimon M
Pituitary; 2015 Aug; 18(4):542-53. PubMed ID: 25280813
[TBL] [Abstract][Full Text] [Related]
24. Somatostatin receptor expression in adrenocortical tumors and effect of a new somatostatin analog SOM230 on hormone secretion in vitro and in ex vivo adrenal cells.
Mariniello B; Finco I; Sartorato P; Patalano A; Iacobone M; Guzzardo V; Fassina A; Mantero F
J Endocrinol Invest; 2011 Jun; 34(6):e131-8. PubMed ID: 21042045
[TBL] [Abstract][Full Text] [Related]
25. Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family.
Attramadal H; Arriza JL; Aoki C; Dawson TM; Codina J; Kwatra MM; Snyder SH; Caron MG; Lefkowitz RJ
J Biol Chem; 1992 Sep; 267(25):17882-90. PubMed ID: 1517224
[TBL] [Abstract][Full Text] [Related]
26. Improved pasireotide response in USP8 mutant corticotroph tumours in vitro.
Albani A; Perez-Rivas LG; Tang S; Simon J; Lucia KE; Colón-Bolea P; Schopohl J; Roeber S; Buchfelder M; Rotermund R; Flitsch J; Thorsteinsdottir J; Herms J; Stalla G; Reincke M; Theodoropoulou M
Endocr Relat Cancer; 2022 Aug; 29(8):503-511. PubMed ID: 35686696
[TBL] [Abstract][Full Text] [Related]
27. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro.
Lesche S; Lehmann D; Nagel F; Schmid HA; Schulz S
J Clin Endocrinol Metab; 2009 Feb; 94(2):654-61. PubMed ID: 19001514
[TBL] [Abstract][Full Text] [Related]
28. Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation.
Ben-Shlomo A; Pichurin O; Barshop NJ; Wawrowsky KA; Taylor J; Culler MD; Chesnokova V; Liu NA; Melmed S
Mol Endocrinol; 2007 Oct; 21(10):2565-78. PubMed ID: 17609435
[TBL] [Abstract][Full Text] [Related]
29. Involvement of histone deacetylase 1/2 in adrenocorticotropic hormone synthesis and proliferation of corticotroph tumor AtT-20 cells.
Hagiwara R; Kageyama K; Niioka K; Takayasu S; Tasso M; Daimon M
Peptides; 2021 Feb; 136():170441. PubMed ID: 33181265
[TBL] [Abstract][Full Text] [Related]
30. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas.
Tateno T; Kato M; Tani Y; Oyama K; Yamada S; Hirata Y
Endocr J; 2009; 56(4):579-84. PubMed ID: 19318729
[TBL] [Abstract][Full Text] [Related]
31. Expression of genes related to corticotropin production and glucocorticoid feedback in corticotroph adenomas of dogs with Cushing's disease.
Teshima T; Hara Y; Takekoshi S; Teramoto A; Osamura RY; Tagawa M
Domest Anim Endocrinol; 2009 Jan; 36(1):3-12. PubMed ID: 18818046
[TBL] [Abstract][Full Text] [Related]
32. Mimecan in pituitary corticotroph cells may regulate ACTH secretion and the HPAA.
Ma QY; Zhang XN; Jiang H; Wang ZQ; Zhang HJ; Xue LQ; Chen MD; Song HD
Mol Cell Endocrinol; 2011 Jul; 341(1-2):71-7. PubMed ID: 21664248
[TBL] [Abstract][Full Text] [Related]
33. Cold inducible RNA binding protein upregulation in pituitary corticotroph adenoma induces corticotroph cell proliferation via Erk signaling pathway.
Jian F; Chen Y; Ning G; Fu W; Tang H; Chen X; Zhao Y; Zheng L; Pan S; Wang W; Bian L; Sun Q
Oncotarget; 2016 Feb; 7(8):9175-87. PubMed ID: 26824322
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin and somatostatin receptors in Cushing's disease.
Hofland LJ
Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
[TBL] [Abstract][Full Text] [Related]
35. Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists.
Kao YJ; Ghosh M; Schonbrunn A
Mol Endocrinol; 2011 Jun; 25(6):1040-54. PubMed ID: 21493671
[TBL] [Abstract][Full Text] [Related]
36. Octreotide and the novel multireceptor ligand somatostatin receptor agonist pasireotide (SOM230) block the adrenalectomy-induced increase in mitotic activity in male rat anterior pituitary.
Nolan LA; Schmid HA; Levy A
Endocrinology; 2007 Jun; 148(6):2821-7. PubMed ID: 17347306
[TBL] [Abstract][Full Text] [Related]
37. β-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly.
Gatto F; Feelders R; van der Pas R; Kros JM; Dogan F; van Koetsveld PM; van der Lelij AJ; Neggers SJ; Minuto F; de Herder W; Lamberts SW; Ferone D; Hofland LJ
Endocrinology; 2013 Dec; 154(12):4715-25. PubMed ID: 24169548
[TBL] [Abstract][Full Text] [Related]
38. Beta-arrestin1 and beta-arrestin2 are differentially required for phosphorylation-dependent and -independent internalization of delta-opioid receptors.
Zhang X; Wang F; Chen X; Li J; Xiang B; Zhang YQ; Li BM; Ma L
J Neurochem; 2005 Oct; 95(1):169-78. PubMed ID: 16181421
[TBL] [Abstract][Full Text] [Related]
39. Targeting the ERK pathway for the treatment of Cushing's disease.
Zhang D; Bergsneider M; Wang MB; Heaney AP
Oncotarget; 2016 Oct; 7(43):69149-69158. PubMed ID: 27708250
[TBL] [Abstract][Full Text] [Related]
40. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas.
Cuevas-Ramos D; Fleseriu M
J Mol Endocrinol; 2014 Jun; 52(3):R223-40. PubMed ID: 24647046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
